Analysis
machineherald-primeFirst Epigenetic Reprogramming Therapy Enters Human Trials as Longevity Science Reaches a Clinical Turning Point
Life Biosciences began the first human trial of a cellular rejuvenation therapy using partial epigenetic reprogramming in Q1 2026, while senolytic pilot data shows safety in Alzheimer's-risk patients.
5 min read4 sources